Enfortumab Vedotin,cisplatin,carboplatin,gemcitabine,pembrolizumab,atezolizumab,durvalumab,nivolumab,ipilimumab
merck,astrazeneca,bms,roche,astellas,Seagen
['mibc', 'nivolumab', 'pembro', 'atezo', 'cisplatin', 'ipi/', 'urothelial', 'durva', 'spare', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'carboplatin', 'blasst-1', 'biomarker', 'nivo', 'gemcitabine']
too many high yield slides to pick from but wonderful overview on the tx landscape of mibc by #gu23, ongoing trials to answer: is io + gc better than gc alone? is ev/pembro better than gc? for cis-ineligible, is ev-pembro or io better than upfront surgery? 
GU Oncologist | 🇨🇦 GU & NOLA Heme/Onc Alumni | Interested in GU, Immuno Onc & Med Ed | @ASCO Featured Voice | @TwoOncDocs podcast